DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
The Da Vinci Robotic-Assisted Surgery system, and Advanced Robotic Surgery Centre was inaugurated early this year
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
The HALO Prostate AI algorithm deployed in HALO AP from Indica Labs
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
Dxcover announced that it will be presenting new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7
Subscribe To Our Newsletter & Stay Updated
